Literature DB >> 19033719

Sexual function in patients with metastatic midgut carcinoid tumours.

Anouk N A van der Horst-Schrivers1, Ellen van Ieperen, A N Machteld Wymenga, H Marike Boezen, Willibrord C M Weijmar-Schultz, Ido P Kema, Wim G Meijer, Wouter W de Herder, Pax H B Willemse, Thera P Links, Elisabeth G E de Vries.   

Abstract

BACKGROUND: Sexual dysfunction is a poorly studied aspect of quality of life in patients with midgut carcinoid tumours. We investigated whether carcinoid patients experience sexual problems.
METHODS: Patients with metastatic midgut carcinoid tumours filled in a validated questionnaire for sexual dysfunction. The prevalence of dysfunction on the subscales arousal, erection, lubrication, orgasm and dyspareunia was compared to a Dutch reference population. Plasma concentration of gonadal hormones, tryptophan and urinary 5-hydroxyindolacetic acid concentrations were measured.
RESULTS: 43 patients were studied, 27 men and 16 women. Sexual dysfunction was present in 29.6% of men and 6.3% of women. The prevalence of sexual dysfunction on the different subscales did not differ from the reference population. Patients with a sexual dysfunction had, compared to those without a sexual dysfunction, a longer duration of disease, 95.3 months (range 5.4-314.5) versus 18.6 months (range 0.6-167.9) (p = 0.024), lower plasma tryptophan concentration (+/-SD) of 31.5 +/- 16.1 and 48.9 +/- 14.5 micromol/l (p = 0.031), and more often used interferon-alpha, 50% of patients versus 10.5% of patients (p = 0.044).
CONCLUSION: Patients with metastatic midgut carcinoid tumours do not experience sexual problems more often than a reference population. Male patients with sexual dysfunction are characterised by more long-standing disease and lower tryptophan concentration. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2008        PMID: 19033719     DOI: 10.1159/000178754

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  10 in total

1.  Do ongoing lifestyle disruptions differ across cancer types after the conclusion of cancer treatment?

Authors:  Kenneth Mah; Andrea Bezjak; D Andrew Loblaw; Andrew Gotowiec; Gerald M Devins
Journal:  J Cancer Surviv       Date:  2010-12-21       Impact factor: 4.442

2.  A randomized trial of a minimal intervention for sexual concerns after cancer: a comparison of self-help and professionally delivered modalities.

Authors:  Janette Perz; Jane M Ussher
Journal:  BMC Cancer       Date:  2015-09-09       Impact factor: 4.430

3.  Perceived causes and consequences of sexual changes after cancer for women and men: a mixed method study.

Authors:  Jane M Ussher; Janette Perz; Emilee Gilbert
Journal:  BMC Cancer       Date:  2015-04-11       Impact factor: 4.430

4.  Feeling well and talking about sex: psycho-social predictors of sexual functioning after cancer.

Authors:  Janette Perz; Jane M Ussher; Emilee Gilbert
Journal:  BMC Cancer       Date:  2014-03-28       Impact factor: 4.430

Review 5.  Effect of Neuroendocrine Neoplasm Treatment on Human Reproductive Health and Sexual Function.

Authors:  Virginia Zamponi; Anna La Salvia; Maria Grazia Tarsitano; Nevena Mikovic; Maria Rinzivillo; Francesco Panzuto; Elisa Giannetta; Antongiulio Faggiano; Rossella Mazzilli
Journal:  J Clin Med       Date:  2022-07-08       Impact factor: 4.964

Review 6.  Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours.

Authors:  Caroline Martini; Eva-Maria Gamper; Lisa Wintner; Bernhard Nilica; Barbara Sperner-Unterweger; Bernhard Holzner; Irene Virgolini
Journal:  Health Qual Life Outcomes       Date:  2016-09-10       Impact factor: 3.186

7.  Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review.

Authors:  Catherine Watson; Craig William Tallentire; John K Ramage; Rajaventhan Srirajaskanthan; Oscar R Leeuwenkamp; Donna Fountain
Journal:  World J Gastroenterol       Date:  2020-07-07       Impact factor: 5.742

Review 8.  Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review.

Authors:  Rohit Gosain; Medhavi Gupta; Arya Mariam Roy; Jonathan Strosberg; Kathryn M Glaser; Renuka Iyer
Journal:  Cancers (Basel)       Date:  2022-03-10       Impact factor: 6.639

9.  Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours.

Authors:  Marianne S Elston; Amanda Love; Dev Kevat; Richard Carroll; Zhen Rong Siow; Sharon Pattison; Veronica Boyle; Eva Segelov; Andrew H Strickland; David Wyld; Richard Gauci; Kim Kennedy; David Ransom
Journal:  Cancer Med       Date:  2021-10-26       Impact factor: 4.452

10.  Efficacy and Safety of 5-Aminolevulinic Acid for Patients with Symptoms of Late-Onset Hypogonadism: A Preliminary Study.

Authors:  Hiroki Koyasu; Shigeo Horie; Kazuhito Matsushita; Takeshi Ashizawa; Satoru Muto; Shuji Isotani; Tohru Tanaka; Motowo Nakajima; Akira Tsujimura
Journal:  World J Mens Health       Date:  2022-01-25       Impact factor: 6.494

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.